Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (4907)	11/27/1997 11:12:00 AM
From: Robert K.	Read Replies (2) \| Respond to of 17367

Here is a copy of the idec/xoma/gne release from 1996.................... FOR RELEASE: May 15, 1996 XOMA Licenses Patent for Anti-CD20 Technology to Genentech and IDEC Pharmaceuticals Xoma to receive $3 million initial payment plus future royalties BERKELEY, CA - May 15, 1996 - XOMA Corporation (Nasdaq: XOMA) today announced the granting of an exclusive license to Genentech, Inc. (NYSE: GNE), including a sublicense to IDEC Pharmaceuticals Corporation (Nasdaq: IDPH), to intellectual property covering the therapeutic use of chimeric IgG1 antibodies specific for the CD20 antigen on the surface of human B-cells. XOMA will receive an initial cash payment of $3,000,000 as well as royalties on the sale of products employing the anti-CD20 technology that are sold in the United States and in other countries where XOMA holds relevant patents. The license relates to XOMA's U.S. Patent #5,500,362, issued March 19, 1996 and entitled "Chimeric Antibody with Specificity to Human B-Cell Surface Antigen", and any related patents or patent applications. IDEC is collaborating with Genentech, F. Hoffman-LaRoche and Zenyaku Kogyo Co. Ltd. on the development and commercialization of IDEC-C2B8, a chimeric anti-CD20 monoclonal antibody. IDEC is currently conducting a Phase III pivotal trial with IDEC-C2B8 in patients with non-Hodgkin's B-cell lymphomas. "This agreement underscores the value of the relationship between XOMA and Genentech," said John P. McLaughlin, executive vice president at Genentech. "Also, by securing a license to XOMA's patents, we gain access to intellectual property that supports our efforts with IDEC to develop an important treatment for non-Hodgkins B-cell lymphoma." "Obtaining a license to this patent provides an extra layer of protection for IDEC-C2B8, in addition to that which it currently enjoys through our proprietary manufacturing technologies and the product's Orphan Drug status," commented William H. Rastetter, Ph.D., president and chief executive officer of IDEC. "We are pleased that XOMA's pioneering chimerization technology can help IDEC and Genentech move forward in the commercialization of a product that could bring significant benefit to patients suffering from non-Hodgkin's B-cell lymphoma," said John L. Castello, XOMA chairman, president and chief executive officer. "This license makes it possible for all parties to realize value from this intellectual property." Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Ten of the currently marketed biotechnology products stem from Genentech research, five of which Genentech markets directly. The company has headquarters in South San Francisco, California, and its stock is traded on the New York and Pacific Stock Exchanges under the symbol GNE. IDEC Pharmaceuticals focuses on developing targeted immunotherapies for the treatment of cancer and autoimmune diseases. IDEC's products are primarily designed to act through immune mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. All of IDEC's products are designed for administration in outpatient settings, providing the opportunity to reduce overall treatment costs. XOMA Corporation is a biopharmaceutical company developing products for the treatment of infections and immunologic disorders. The company is focused primarily on the accelerated development of products derived from a human host-defense protein, BPI (bactericidal/permeability-increasing protein). Neuprex, XOMA's first BPI-derived product, is currently in clinical trials for four different indications..

To: Robert K. who wrote (4907)	11/27/1997 12:57:00 PM
From: aknahow	Respond to of 17367

Bob nytimes article states sales wll start in 2 weeks. Supprised at how much FDA is saying about this breakthrough, and how enthusiastic they are. Clearly this must be a big, big deal. I have now heard it countless times on the raidio. Only have two hands and in the car only can only take one off the wheel. (wifes rule). Don't even know if they all mention GNE or IDPH (IDEC) my point being the anguish I felt at not seeing XOMA mentioned re P II meningo. was perhaps misplaced. There are many audiences and it perhaps is not reasonable to expect cos name to be mentioned in each of them. BTW the FDA certainly knows XOMA was inolved and that to me is important. Great article on CORR in IBD. Don't own, mentioned only for type of thing Xoma can expect if it has winner. Corr drug integrllin not yet even approved.